Skip to content
ClinCalc Pro
Menu
Combined oral contraceptive Pregnancy: Norinyl-1 is not indicated during pregnancy. If pregnancy occurs during medication with Norinyl-1, treatment should be withdrawn immediately. Like all norethisterone derivatives used for contraception, Norinyl-1 has slight androgenic activity. At doses higher than normally used in OC and HRT formulations, masculinisation of female foetuses has been observed. The results of most epidemiological studies to date relevant to inadvertent foetal exposure to combinations of oestrogens with progestogens, indicate no teratogenic or foetotoxic effects. Breast-feeding: patients who are fully breast-feeding should not take Norinyl-1 tablets since, in common with other combined hormonal contraceptives, the oestrogen component may reduce the amount of milk produced. In addition, active ingredients or their metabolites have been detected in the milk of mothers taking oral contraceptives. The effect of Norinyl-1 on breast-fed infants has not been determined.

Norethisterone with mestranol

Brand names: Norinyl-1

This is a fixed-dose combined oral contraceptive pairing the progestogen norethisterone with the oestrogen mestranol, used for contraception and cycle control.

Adult dose

Dose: Oral contraception: 1 tablet (each tablet contains norethisterone 1 milligram and mestranol 50 micrograms) taken at the same time each day from the first day of the menstrual cycle. Subsequent cycles: no tablets for 7 days, then a new course of 1 tablet daily for the next 21 days. This sequence of 21 days on treatment, 7 days off treatment is repeated for as long as contraception is required
Route: Oral
Frequency: Once daily at the same time each day for 21 days, then 7 tablet-free days; repeat
Source: UK SPC for Norinyl-1 via MHRA Products. SPC §2: 'Each tablet contains 1 milligram norethisterone and 50 micrograms mestranol' (also 41.47 mg lactose as monohydrate). §4.1: 'Norinyl-1 is indicated for oral contraception.' §4.2 (verbatim): 'The dosage of Norinyl-1 for the initial cycle of therapy is 1 tablet taken at the same time each day from the first day of the menstrual cycle. For subsequent cycles, no tablets are taken for 7 days, then a new course is started of 1 tablet daily for the next 21 days. This sequence of 21 days on treatment, seven days off treatment is repeated for as long as contraception is required.' Starting day: 'Patients unable to start taking Norinyl-1 tablets on the first day of the menstrual cycle may start treatment on any day up to and including the 5th day of the menstrual cycle'; patients starting on day 1 are protected at once, those delaying to day 5 may not be protected immediately and another method of contraception is recommended for the first 7 days of tablet-taking (condoms, caps plus spermicides, intra-uterine devices; the rhythm, temperature and cervical-mucus methods should not be relied upon). Missed tablets: if a tablet is missed within 12 hours of the correct dosage time, take it as soon as possible, even if this means taking 2 tablets on the same day. If one or more tablets are missed for more than 12 hours, take the last missed tablet as soon as possible, continue the rest in the normal manner, and use extra contraceptive protection (e.g. a condom) for the next 7 days. Patients who have missed one or more of the last 7 tablets in a pack should start the next pack as soon as the present one has finished (without the normal seven day gap). Changing from another oral contraceptive: take the first dose of Norinyl-1 on the day immediately after finishing the previous pack. After childbirth (not breast feeding): first dose on the 21st day after childbirth; if the first dose is delayed, contraception may not be established until 7 days after the first tablet and extra contraceptive methods will be necessary. After a miscarriage or abortion: first dose the next day, with immediate protection. Vomiting or diarrhoea (gastro-intestinal upsets) may interfere with absorption and reduce contraceptive efficacy: continue the tablets but also use another contraceptive method during the upset and for the next 7 days (§4.4). Some drugs may modify the metabolism of Norinyl-1 and reduce effectiveness (certain sedatives, antibiotics, anti-epileptic and anti-arthritic drugs): use mechanical contraception as well while such agents are used (§4.5). Discontinue at least four weeks before, and for two weeks following, elective operations and during immobilisation; after injection treatment for varicose veins do not resume until 3 months after the last injection (§4.4). After the age of thirty-five years the patient and physician should carefully re-assess the risk/benefit ratio of combined hormonal contraceptives (§4.4). Patients who are fully breast-feeding should not take Norinyl-1 (§4.6). The SPC §4.2 gives no maximum dose and no separate paediatric or elderly dosing. TRUNCATION: the retrieved §4.4 text is cut off at the source-fetch limit, so any later §4.4 warnings were not retrieved.

Dose adjustments

Renal

No renal dose adjustment is stated in the SPC; kidney disease is listed among conditions in which women taking oral contraceptives require careful observation (§4.4).

Hepatic

Acute or severe chronic liver disease, including liver tumours, Dubin-Johnson or Rotor syndrome, is a contraindication (§4.3); progestogen oestrogen preparations should be used with caution in patients with a history of hepatic dysfunction or hypertension (§4.4). No dose adjustment is given.

Dose independently re-sourced from UK Summary of Product Characteristics (SPC) via MHRA Products — clinician-reviewed. Always confirm against the product SmPC and your local formulary before prescribing.

Contraindications

  • Hypersensitivity to the active substances or to any of the excipients
  • History of confirmed venous thromboembolic disease (VTE), family history of idiopathic VTE and other known risk factors of VTE
  • Thrombophlebitis, cerebrovascular disorders, coronary artery disease, myocardial infarction, angina, hyperlipidaemia or a history of these conditions
  • Acute or severe chronic liver disease, including liver tumours, Dubin-Johnson or Rotor syndrome
  • History during pregnancy of idiopathic jaundice, severe pruritus or pemphigoid gestationis
  • Known or suspected breast or genital cancer; known or suspected oestrogen-dependent neoplasia
  • Undiagnosed abnormal vaginal bleeding
  • A history of migraines classified as classical focal or crescendo
  • Pregnancy
  • Concomitant use of medicinal products containing ombitasvir/paritaprevir/ritonavir and/or dasabuvir

Side effects

  • Slight nausea at first, weight gain or breast discomfort, which soon disappear
  • Gastro-intestinal symptoms, changes in libido and appetite, headache, exacerbation of existing uterine fibroid disease, depression, and changes in carbohydrate, lipid and vitamin metabolism
  • Spotting or bleeding during the first few cycles; menstrual bleeding usually becomes light and occasionally there may be no bleeding during the tablet-free days
  • Hypertension (usually reversible on discontinuing treatment) in a small percentage of women
  • Venous thromboembolism - all combined hormonal contraceptives increase the risk; norethisterone-containing products are associated with the lowest risk, and the risk is highest in the first ever year of use (§4.4)
  • Arterial thrombosis risk increases with age and is aggravated by cigarette smoking; benign and malignant liver tumours and gall bladder disease have been associated with oral contraceptive use (§4.4)

Interactions

  • St John's wort (Hypericum perforatum) - should not be taken concomitantly: potential loss of contraceptive effect
  • Certain sedatives, antibiotics, anti-epileptic and anti-arthritic drugs - may modify the metabolism of Norinyl-1 and reduce effectiveness; use mechanical contraceptives as well
  • Ombitasvir/paritaprevir/ritonavir and dasabuvir, with or without ribavirin - contraindicated (risk of ALT elevations); switch to an alternative contraceptive method before starting and Norinyl-1 can be restarted 2 weeks after completing that regimen
  • Laboratory tests - results (biochemical markers of thyroid and liver function; plasma levels of carrier proteins, triglycerides, coagulation and fibrinolysis factors) may be influenced by oestrogen-containing oral contraceptives

Monitoring

  • Personal and family medical history before starting and at regular intervals; measure blood pressure and, if judged appropriate by the clinician, breast, abdominal and pelvic examination including cervical cytology
  • Regular surveillance for thromboembolism and cardiovascular conditions
  • Careful observation in women with breast nodules, fibrocystic breast disease, uterine fibroids, a history of severe depressive states, varicose veins, sickle-cell anaemia, diabetes (glucose tolerance may decrease), hypertension, cardiovascular disease, migraine, epilepsy, asthma and the other conditions listed in §4.4
  • Discontinue if there is loss of vision or ocular changes, onset or aggravation of migraine, or a new recurrent, persistent or severe headache
  • Right upper quadrant mass or tenderness or acute abdomen - consider a liver tumour

Clinical monograph

How it works

Mestranol (a prodrug converted to ethinylestradiol) and norethisterone together suppress gonadotrophin release to inhibit ovulation, while also thickening cervical mucus and altering the endometrium.

Prescribing in practice

  • As a combined oestrogen-containing preparation it raises the risk of venous and arterial thromboembolism and is contraindicated where this risk is high, such as migraine with aura, established cardiovascular disease, or smoking in older women.
  • Efficacy may be reduced by enzyme-inducing drugs, and the woman should be assessed against UK Medical Eligibility Criteria before starting.
  • Counsel on what to do about missed pills and that additional precautions may be needed in certain situations.

Monitoring

Check blood pressure and review thrombotic and cardiovascular risk factors before starting and periodically during use.

Counselling the patient

  • Take it regularly and follow the missed-pill instructions to keep contraceptive cover.
  • Stop and seek urgent care for severe leg pain or swelling, chest pain, breathlessness, or sudden severe headache or visual change.
  • Tell your clinician about migraines with aura, smoking, and any new medicines.

Evidence & guidelines

Combined oral contraceptives are prescribed in line with the UK Medical Eligibility Criteria and Faculty of Sexual and Reproductive Healthcare guidance.

Reference: FSRH; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. The structured dose values shown have been reviewed by a clinician. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.